Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.300
-0.270 (-7.56%)
Apr 21, 2026, 4:00 PM EDT - Market closed
Editas Medicine Employees
Editas Medicine had 87 employees as of December 31, 2025. The number of employees decreased by 159 or -64.63% compared to the previous year.
Employees
87
Change (1Y)
-159
Growth (1Y)
-64.63%
Revenue / Employee
$465,747
Profits / Employee
-$1,839,770
Market Cap
322.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 87 | -159 | -64.63% |
| Dec 31, 2024 | 246 | -19 | -7.17% |
| Dec 31, 2023 | 265 | 39 | 17.26% |
| Dec 31, 2022 | 226 | -38 | -14.39% |
| Dec 31, 2021 | 264 | 29 | 12.34% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 229 |
| LENZ Therapeutics | 152 |
| Zentalis Pharmaceuticals | 106 |
| Silence Therapeutics | 88 |
| Prelude Therapeutics | 79 |
| Rezolute | 75 |
| Immuneering | 53 |
| Surrozen | 44 |
EDIT News
- 25 days ago - Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference - GlobeNewsWire
- 6 weeks ago - Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates - GlobeNewsWire
- 2 months ago - Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Genflow Biosciences PLC Announces Directorate Change - Accesswire
- 5 months ago - Editas Medicine Announces Third Quarter 2025 Results and Business Updates - GlobeNewsWire
- 6 months ago - Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025 - GlobeNewsWire
- 6 months ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 7 months ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire